Celgene, Elan settle Abraxane case for $78M; Health groups ask Novartis to back off Gleevec patent;

Patents on file

@FiercePharma: AZ's dental unit attracts a slew of suitors. Story | Follow @FiercePharma

> Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene breast cancer drug Abraxane. In return, Celgene gets a worldwide license to several of Elan's related patents. Report

> Novartis has been urged to drop its "persistent legal actions" in India regarding patent coverage for its anticancer drug Glivec and a challenge to the country's patent laws over fears the latter could hinder access to medicines. News

> Irish drugmaker Shire said Watson Pharmaceuticals is seeking marketing approval for a new generic version of the attention deficit hyperactivity disorder treatment Adderall XR. Story

> Valeant Pharmaceuticals posted cash earnings and revenue that topped expectations for its first full quarter since combining with Canada's Biovail, sending its shares higher. Item

> Specialty pharmaceutical company Warner Chilcott's Q4 profit marched past market expectations, helped by sales from products acquired from Novartis and Procter & Gamble. Article

> The FDA has teamed up with Georgetown University to do joint research on public health, ethics, bioinformatics and more, and to cooperate on training and continuing education. Report

Biotech News

@FierceBiotech: Pfizer's crizotinib eliminates signs of advanced lymphoma. Report | Follow @FierceBiotech

@JohnCFierce: Coviden, Valeant vet Chuck Bramlage named CEO at Pearl Therapeutics. News | Follow @JohnCFierce 

> Two European cell therapy companies merge. Item

> FDA hands Protalix a CRL for Gaucher's disease drug. News 

> Osage closes lid on $100M war chest for university start-ups. Story

> Lilly neuroscience chief steps down. Report

And Finally... A rising PSA level isn't such a good predictor of prostate cancer after all and can lead to many unnecessary biopsies, says a large new study. Report